About Agenus Inc.
https://www.agenusbio.comAgenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
CEO
Garo H. Armen
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-12 | Reverse | 1:20 |
| 2023-04-26 | Forward | 1019:1000 |
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:2.57M
Value:$12.03M
BLACKROCK FUND ADVISORS
Shares:2.35M
Value:$11M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:2.09M
Value:$9.76M
Summary
Showing Top 3 of 127
About Agenus Inc.
https://www.agenusbio.comAgenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $30.23M ▲ | $10.54M ▼ | $63.91M ▲ | 211.39% ▲ | $2 ▲ | $80.11M ▲ |
| Q2-2025 | $25.69M ▲ | $15.45M ▼ | $-27.95M ▼ | -108.81% ▼ | $-1 ▲ | $-13.55M ▼ |
| Q1-2025 | $24.07M ▼ | $15.72M ▼ | $-25.27M ▲ | -104.99% ▲ | $-1.03 ▲ | $-10.37M ▲ |
| Q4-2024 | $26.84M ▲ | $18.84M ▲ | $-45.86M ▲ | -170.88% ▲ | $-2.04 ▲ | $-22.86M ▲ |
| Q3-2024 | $25.11M | $15.41M | $-66.39M | -264.36% | $-3.08 | $-28.14M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.46M ▼ | $233.89M ▲ | $514.76M ▼ | $-274.14M ▲ |
| Q2-2025 | $9.53M ▼ | $185.22M ▼ | $521.53M ▼ | $-354.6M ▼ |
| Q1-2025 | $18.49M ▼ | $200.2M ▼ | $522.6M ▼ | $-341.85M ▼ |
| Q4-2024 | $40.44M ▼ | $226.27M ▼ | $532.7M ▲ | $-326.38M ▼ |
| Q3-2024 | $44.78M | $238.48M | $510.29M | $-292.34M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $63.91M ▲ | $-14.74M ▲ | $76K ▼ | $6.68M ▼ | $-8M ▲ | $-14.74M ▲ |
| Q2-2025 | $-30.01M ▼ | $-20.22M ▲ | $281K ▲ | $10.94M ▲ | $-8.95M ▲ | $-20.22M ▲ |
| Q1-2025 | $-26.37M ▲ | $-25.62M ▲ | $57K ▲ | $3.59M ▼ | $-21.95M ▼ | $-25.62M ▲ |
| Q4-2024 | $-45.86M ▲ | $-28.65M ▲ | $-21K ▼ | $24.37M ▲ | $-4.35M ▲ | $-28.73M ▲ |
| Q3-2024 | $-67.21M | $-53.29M | $56K | $4.56M | $-48.94M | $-53.3M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Non Cash Royalty Revenue | $80.00M ▲ | $20.00M ▼ | $20.00M ▲ | $30.00M ▲ |
 Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $50.00M ▲ | $30.00M ▼ | $20.00M ▼ | $30.00M ▲ |
CEO
Garo H. Armen
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-12 | Reverse | 1:20 |
| 2023-04-26 | Forward | 1019:1000 |
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:2.57M
Value:$12.03M
BLACKROCK FUND ADVISORS
Shares:2.35M
Value:$11M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:2.09M
Value:$9.76M
Summary
Showing Top 3 of 127